A plethora of studies revealed that BRAFV600E controls a network of genes crucial in integrating and regulating the extracellular and intracellular signalling in thyroid cancer cells through the p‐MEK1/2 and p‐ERK1/2 pathway, which may be fundamental to trigger an abnormal cell differentiation/totipotency and shape/polarity, and contribute to tumour aggressiveness. The gene discussed is MAP2K1; the disease is thyroid gland carcinoma.